Rising incidences of CVDs have been linked to poor diet, lack of physical activity, tobacco use, excessive alcohol consumption, high blood pressure, and genetic predisposition. Repatha evolocumab ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

Amgen, Inc. ( NASDAQ: AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - ...

It isn’t known whether you can receive Repatha during pregnancy. There’s not enough information from the drug’s clinical trials or other studies about the use of Repatha in pregnant people.

Presentation Unidentified Speaker Thank you. Thank you, Julianne. Good afternoon, everyone, and welcome to our 4th-quarter ...

In the UK meanwhile, even with the discounted price on offer for Repatha, there have been suggestions that the drug may see its use restricted, with the National Institute for Health and Care ...

Adding the PCSK9 inhibitor led to greater absolute reductions in CVD risk than in younger patients, with no signs of safety ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

Sales of Repatha grew slowly since launch to reach ... New cardiovascular outcomes data has helped the two drugs build a case for broader use, but they are also facing a challenge from a new ...

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...

Amgen expects phase 3 data later this year for atopic dermatitis drug rocatinlimab and gastric cancer drug bemarituzumab and also data for Repatha in ... How we use your information depends ...